ORIC reports Q3 2022 cash of $218M; pipeline studies on track for data in 1H 2023

Oric Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.73

Cash and investments of $218.0M as of Sep 30, 2022; expected to fund operations into 2H 2024.
R&D expenses $14.7M (up from $12.9M); G&A $6.0M (up from $5.6M); IPR&D $5.0M milestone for ORIC-114.
Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in 1H 2023.
FDA cleared US IND for ORIC-114; Phase 1b enrolling in South Korea with expansion to US.
Preclinical data on ORIC-533 (CD73 inhibitor) to be presented at ASH Annual Meeting Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.